Lymphoma Trial, Recruiting (NCT06043011)

Lymphoma Trial, Recruiting NCT06043011 Sponsor: iOMEDICO AG Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06043011 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People who have a confirmed diagnosis of the specific type of non-Hodgkin lymphoma (NHL) the trial is studying
For living patients, a signed consent form is required — for those taking part in the patient-reported outcomes (survey) portion, this must be signed before or on the day treatment begins; for those not taking part in the survey portion, this must be signed no later than eight weeks after treatment begins

Who may not be able to join:

People who have not received any systemic (whole-body) treatment for their lymphoma condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rainer Claus, Prof. Dr., Universitätsklinikum Augsburg, Germany

Phone: +4976115242

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06043011

Sponsor: iOMEDICO AG

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +4976115242

More information: https://clinicaltrials.gov/study/NCT06043011

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People who have a confirmed diagnosis of the specific type of non-Hodgkin lymphoma (NHL) the trial is studying
For living patients, a signed consent form is required — for those taking part in the patient-reported outcomes (survey) portion, this must be signed before or on the day treatment begins; for those not taking part in the survey portion, this must be signed no later than eight weeks after treatment begins

Who may not be able to join:

People who have not received any systemic (whole-body) treatment for their lymphoma condition

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

iOMEDICO AG

Registry

ClinicalTrials.gov

Start date

27 September 2023

Est. completion

1 December 2033

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Course of treatment (treatment reality)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov